Conditions: Obesity Overactive Bladder Incontinence
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 127
Healthy volunteers: no

Brief summary:
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

Detailed description:

Arms:
arm 1: Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks. arm 2: Placebo capsule taken orally once daily for 14 weeks.

Interventions: intervention 1: Trospium Chloride, Extended Release (XR) intervention 2: placebo
Intervention descriptions: intervention 1: Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks. intervention 2: Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.

Protocol document: